Introduction
Registries have been very useful for the collection of observational safety data of biologics in a large number of patients for much longer periods than would occur in controlled clinical trials. Registry data are collected from typical clinical practice, and represent treatment safety in a real-life clinical setting.
In Crohn's disease [CD] , infliximab is typically considered for moderate to severe disease when conventional treatments produce inadequate responses or when fistulising disease is present. 1 Because infliximab can help maintain remission over time, 2 evidence about longer-term use is important. The TREAT Registry [Crohn's Therapy, Resource, Evaluation, and Assessment Tool] was a prospective, cross-sectional, observational, multicentre long-term registry of adult patients with CD who were recruited in community-based and academic practice settings in the USA. This registry was initiated in 1999 to evaluate the clinical safety outcomes of various treatment regimens, including infliximab, in the management of CD. In TREAT, patients already on infliximab [Remicade ® ] were eligible for inclusion as were patients on other ongoing Crohn's therapies. In ENCORE, on the contrary, patients in the infliximab group were naïve to infliximab at baseline and were new candidates for infliximab therapy because they were failing conventional therapy. As a result, TREAT included patients who were tolerating infusions and were [most probably] responding to infliximab, whereas in ENCORE patients still needed to receive induction therapy with associated risk of non-tolerance and primary non-response. This may have influenced the results, due to a positive selection of patients tolerating infliximab in TREAT. The mean length of patient follow-up in TREAT was 5.2 years. 3 The data from the TREAT registry have enabled a better understanding of the long-term safety of infliximab vs conventional therapies in adult CD, including the incidence of serious infections, cancer, and mortality. 2, 3 The ENCORE registry [European National Crohn's Observational REgistry] was also a prospective registry study of adult patients with CD treated under typical practice conditions during 5 years of follow-up. In contrast to the TREAT registry, data from the ENCORE registry were collected in European countries and included patients treated with conventional therapies and patients who started infliximab or were switched from conventional to infliximab therapy. The primary objective of ENCORE was to collect long-term safety data during and after exposure to infliximab vs conventional therapies. Here, we report baseline characteristics and primary safety data after completion of the entire 5-year follow-up phase. . The ENCORE protocol was approved by the institutional review boards at each participating site, and all patients provided written informed consent before participation. Crohn's disease patients were eligible when treatment intensification such as introduction of corticosteroids, the addition of an immunodulator, and/or initiation of infliximab therapy, was indicated. Patients were adults aged ≥ 18 years, with a diagnosis of active luminal or fistulising CD with no previous exposure to anti-tumour necrosis factor [TNF] treatment. Patients with active and untreated latent tuberculosis, lymphoproliferative disorders, malignancies, or moderate or severe heart failure NYHA class III/IV were excluded. Patients were followed for 5 years, with the last patient's last visit in February 2013. A limited number of non-Caucasian patients were recruited in ENCORE; therefore the results of this registry should not be automatically adopted to minority races with increasing CD incidence in the European territory.
Materials and Methods

Design and patients
Procedures
Crohn's disease patients eligible for infliximab therapy according to the European product label were screened, started in the ENCORE registry with informed consent, and received the first infusion within the following 30 days. Physicians, in conjunction with their patients, made all treatment decisions, including the decision to switch treatments. Study visits occurred at least every 6 months. All patients were naïve to anti-TNF or other biologics and were grouped by the treating physician according to the treatments they received during the study as follows.
1. Infliximab therapy: patients were scheduled to receive infliximab within 30 days of the enrolment visit. 2. Conventional therapy: patients received conventional therapies without anti-TNF agents. Patients whose CD was not adequately controlled were offered an alternative treatment that did not include infliximab. 3. Switched to infliximab: patients in the conventional therapy group switched to infliximab at any point during the follow-up period.
The evaluation of safety was based on adverse events [AEs] reported by the treating physician using a standardised form at every 6-monthly visit. Patients were asked to describe all AEs that occurred since the previous visit. Events were recorded for seven pre-specified AE categories: serious infections; infusion-related reactions [IRRs] ; haematological conditions [e,g. thrombocytopenia, neutropenia, pancytopenia, granulocytopenia, leukopenia, and aplastic anaemia]; congestive heart failure; demyelinating neurological disorders; lymphoproliferative disorders and malignancies; fatalities; and any other important medical events and serious AEs.
Statistical analyses
Patients who started on infliximab [Remicade ® ] constituted the infliximab group. Patients who started on conventional therapies constituted the conventional therapy group, regardless of whether they continued conventional therapy or switched to treatment other than infliximab. However, the data of patients who started on conventional therapy and switched to infliximab were included in the conventional therapy group until the time of switch; after the switch, their data were included in the switched-to-infliximab group. In some analyses, all patients in the infliximab and switched-to-infliximab groups were combined in a 'total infliximab' group.
For the purposes of the analyses, patients who entered the registry in the infliximab group stayed in that group until the end of the observation period even if they discontinued infliximab treatment. For patients who were enrolled in the conventional therapy group, duration of follow-up lasted from enrolment to the last visit or to the time of the first dose of infliximab. For patients who switched to infliximab, the duration of follow-up was from the time of the switch to the last visit.
Safety data were analysed in four different ways: 1] frequency of all observed AEs; 2] incidence rate per 1000 person-years [PY] of follow-up for the seven pre-specified AE categories and serious AEs adjusted for the time of exposure vs non-exposure to infliximab using the 90-day rule; 3] multivariable analysis to assess treatment effect [infliximab group vs conventional therapy group comparison only] using a Cox proportional hazards model; and 4] multivariable analysis taking into consideration the timing of the latest dose of infliximab relative to the onset of AEs [within 90 days of the latest dose] in PY using Poisson regression. Exposure time using this 90-day rule was from the first infliximab dose until 90 days after end of infliximab therapy, death, or end of data collection, whichever came first. Non-exposure [to infliximab] time for conventionaltherapy patients was from entry into the registry until switching to infliximab. The 90-day rule was not applied to malignancies; here, the risk window for infliximab therapy started from the onset of infliximab therapy until the end of data collection, even if the patient switched to another biologic agent. The Cox proportional hazards model was performed using stepwise selection to identify prognostic demographic and baseline disease variables including age, gender, fistula status [yes/no], current smoking status [yes/no], disease severity [HarveyBradshaw Index], disease duration, prednisone use, and immunosuppressive use. Since the numbers of congestive heart failure [CHF] and demyelinating neurological disorder events were very small, the multivariable model was not fitted for these AEs. In order to limit the number of prognostic variables in the multivariable model for each of the event types, each prognostic variable was first evaluated in a univariable model and selected for inclusion in the multivariable model if it was significant at alpha = 0.10 level.
The Poisson regression analysis used the same set of prognostic covariates as used in the Cox proportional hazards model, and each variable was first evaluated in a univariable model and selected for inclusion in the multivariable model if it was significant at alpha = 0.10 level. 
Results
Patient disposition
Patient demographic and baseline characteristics
The treatment groups were comparable at baseline with respect to demographic characteristics, including age, gender distribution, and race. The infliximab and switched groups, however, had more severe disease at baseline than the conventional therapy group [greater Harvey-Bradshaw Index, longer disease duration, and more CD-related surgeries; Table 1 ]. Smoking status at baseline was not different between groups. A history of perianal fistulising CD and presence of draining fistula 4 weeks before the baseline visit was greater in the infliximab group than in the conventional therapy or switched groups.
Concomitant medication at baseline
The most common CD-related medications used at baseline are shown in Table 1 . Thiopurines [azathioprine/6-mercaptopurine], antibiotics, methotrexate, and narcotic analgesics were used more often in the infliximab [Remicade ® ] group than the conventional therapy group [ Table 1 ]. In contrast, corticosteroid medications and sulphasalazine/5-aminosalicylic acid were used more often in the conventional therapy group in than the infliximab group. 
Follow-up duration and exposure to infliximab
Serious infections
The most common serious infections reported in the infliximab [ [7] , anal [6] , abdominal wall [3] , and abdominal [2] . Patients exposed to infliximab [vs nonexposed] had a higher rate of serious infections when applying the 90-day rule [26.6 vs 17.3/1000 PY exposure; p = 0.0008] [ Table 4 Table 4 ].
In the Cox proportional hazards model, infliximab [vs conventional therapy] was associated with an increased risk of serious Table 4 ]. Among patients with at least one intermittent dose, the rate of IRRs occurring with infusions given at least 90 days after the previous infusion was 1.5% and similar to the rate of IRRs reported in patients who never had an intermittent dose [1.4%].
Haematological conditions
Benign haematological conditions were reported in 50, 7, and 11 patients in the infliximab [Remicade ® ] group, the switched to infliximab group, and the conventional group, respectively [ Exposure was defined as the number of days between the first infliximab dose and the last infliximab dose. If the first infliximab dose was before baseline, the first dose was considered to be the baseline date.
Min, minimum; max, maximum; SD, standard deviation. AEs leading to fatality are presented under both their specified category and fatalities. AEs for the switched-to-infliximab group include AEs occurring on or after the time of switch.
[ 
Demyelinating neurological disorders
In the infliximab [Remicade ® ] group, 4/1541 patients were reported to have developed demyelinating neurological disorders [one patient each of multiple sclerosis, dysaesthesia, optic neuritis, and radiculopathy]. In the conventional therapy group, 1/1121 had multiple sclerosis. Comparison of the rate of events per 1000 PY exposure did not identify any differences between patients who were exposed to infliximab vs those who were not exposed [p = 0.6121] [ Table 4 ]. There were too few demyelinating events to analyse in the Cox model.
Lymphoproliferative disorders and malignancies
Lymphoproliferative disorders and malignancies were reported for 49/1541 patients [3.2%] in the infliximab group, 21/1121 [1.9%] in the conventional therapy group, and 8/298 [2.7%] in the switched group [ Table 3 ]. The most common lymphoproliferative disorders/ malignancies in the infliximab, conventional, and switched groups were lymphoma [9, 0, and 0 patients, respectively], basal cell carcinoma [5, 6 , and 0 patients, respectively], and breast cancer [5, 3, and 0 patients, respectively]. The lymphoma cases included four Hodgkin, four B-cell, and one metastatic lymphoma. Five lymphoma cases were on concomitant AZA or methotrexate [MTX] . One lymphoma case resolved upon discontinuation of MTX. Three of nine lymphoma patients died during follow-up. No cases of hepatosplenic T-cell lymphoma were reported in ENCORE. In the infliximab, conventional, and switched groups, colon cancer was reported in 6, 1, and 0 patients, respectively; rectal cancer was reported in 5, 1, and 1 patients, respectively, and small intestine cancer was reported in 1, 0, and 1 patient, respectively.
Exposure-adjusted rate of lymphoproliferative disorders and malignancy was not different for infliximab exposure [ For serious infections, congestive heart failure, and haematological conditions, only the first event per patient, and any subsequent events which start more than 30 days apart, are considered unique events [within each system organ class]. c For demyelinating neurological disorders and lymphoproliferative disorders and malignancies, unique events are the first event for each patient within each system organ class. All infusion-related reactions are considered unique events. d p-Value from multivariable model adjusted for additional covariates as follows: serious infections: fistula status, disease duration, prednisone use 6 months preceding baseline, immunomodulator use 6 months preceding baseline; haematological conditions: none; fatalities: age, fistula status, disease severity, disease duration, prednisone use 6 months preceding baseline, immunomodulator use 6 months preceding baseline; demyelinating neurological disorder: immunomodulator use 6 months preceding baseline; lymphoproliferative disorders and malignancies: age and disease duration. 3.11. Congestive heart failure CHF was reported in one patient in the conventional therapy group and one patient in the infliximab group; no cases of CHF were reported in the group that switched to infliximab [ Table 3 ]. 
Fatalities
In all 48 deaths were reported: 30 patients receiving infliximab [Remicade ® ], 14 patients receiving conventional therapy, and 4 patients who switched to infliximab [ Table 3 ]. Cause of death is shown in Table 7 . A lymphoproliferative disorder/malignancy was the reported cause of death in 19/48 cases [39.6%]. In the analysis of mortality rates adjusted for exposure, there was an increased mortality rate in the group of patients who were not exposed to infliximab [5.5 fatalities per 1000 PY] compared with patients who were exposed [1.9 fatalities per 1000 PY] [p = 0.023]. Mortality rate/1000 PY infliximab exposure trended to be lower in patients on AZA/6MP combination therapy [ Table 4 ]. In Cox PH analysis, there was no increased risk of death in the patients receiving infliximab [HR = 
Discussion
Results from the ENCORE registry add important information about the long-term safety of infliximab [Remicade ® ] treatment in a large number of adult patients with CD. Exposure to conventional treatments and/or infliximab in ENCORE largely reflects clinical practice in Europe at the time the registry started, now more than 10 years ago. Not surprisingly, patients starting infliximab treatment entered the registry with higher disease burden [in particular, higher Harvey-Bradshaw activity scores, more fistulising disease, longer disease duration, and more CD-related surgeries]. The majority of patients completed the 5-year study. There were 19.7% of patients who were lost to follow-up; this may be due to the observational nature of this registry, with only two study visits per year. The proportion of patients lost to follow-up in this study is considerably smaller than the 45% of patients who were lost to follow-up in the TREAT study. The high proportion of intermittent infliximab treatment [45%] may be due to several factors, including the long duration of followup, the strict definition of intermittent treatment [> 90 days between two consecutive infusions at any time during the 5-year followup], and the more commonly used 'episodic' treatment when the ENCORE registry was initiated in 2003. Currently, fewer patients would receive intermittent treatment, because of findings from the prospective ACCENT-1 and SONIC trials. 2, 5 It is also possible that patients in ENCORE who achieved sustained remission preferred to interrupt treatment. However, no efficacy data were collected in ENCORE, and the proportion of patients in remission who moved to intermittent therapy is unknown. Intermittent or episodic treatment has been associated with development of antibodies to infliximab [ATI], which has been associated with infusion reactions. 6 In ENCORE, the overall incidence of IRRs per number of infusions was low and similar between those patients who had at least one intermittent dose and those who never had an intermittent dose. ATIs were not measured in ENCORE.
Our data confirm that infliximab exposure increases the risk of serious infection. In patients on infliximab, combination therapy with AZA/6-MP and on monotherapy, the serious infection incidence rates/1000 patient years were 25.4 and 39.1, respectively, and not different as shown by the overlapping confidence intervals. In multivariable analysis, patients treated with infliximab had a statistically significantly increased rate [i.e. 64% increase] of serious infections vs those who were treated with conventional therapies. In the Cox model of time to first event, prednisone use during the study was not associated with increased risk of serious infection; after adjusting for infliximab exposure and based on the 90-day rule, however, the use of prednisone during the study significantly increased the risk rate of serious infection, with 75% in the Poisson regression analysis, which is consistent with findings from both the TREAT 3 and the Leuven 7 cohorts. In ENCORE, the risk of haematological conditions was increased with infliximab [Remicade ® ] treatment [HR = 2.91], and age [HR = 1.02]. These non-malignant haematological conditions, including leukopenia, neutropenia, and thrombocytopenia, are mainly due to the immunosuppressive effect of combination therapy with AZA/6-MP. Indeed, 45/46 cases of haematological conditiosn were observed in patients with AZA/6-MP co-medication, with rates/1000 PY exposure of 12.5, 13.3, and 3.3 for all infliximab patients, and those with and without AZA/6-MP co-medication, respectively. Haematological reactions, including pancytopenia, leucopenia, neutropenia, and thrombocytopenia, have been reported in patients receiving TNF blockers, including infliximab. 1 Higher myelotoxic activity of combination therapy may be due to 6-thioguanine [6TGN] in CD patients treated with AZA and infliximab combination therapy, 8 especially in patients with low thiopurine methyltransferase. 9 The unadjusted rate of malignancy for infliximab [Remicade ® ]-treated patients in TREAT was 6.4/1000 PY [2] which is comparable to our finding of 7.6/1000 PY total exposure.
Deserving further attention is the occurrence of lymphoma in this registry. Although lymphoma was not a pre-specified category of serious AE, we observed that there were nine cases of lymphoma, all occurring in the infliximab group. Importantly, the duration of infliximab exposure was usually short before lymphoma diagnosis, with four of the nine cases having received three or fewer infusions. It remains unknown whether short infliximab exposure in CD patients may be a causal factor for lymphoma. In a recent metaanalysis of lymphoma risk with AZA/6-MP use, the overall standardised incidence ratio [SIR] of lymphoma was 4.92, with a clear difference between population-based studies [SIR 2.80] and referral centre studies [SIR 9.24] . 10 In this study, long-term immunosuppression, rather than direct DNA damage, may have been more of a factor in the development of excess lymphomas. In ENCORE, combination therapy was associated with haematological conditions of myelosuppression. Another retrospective registry study determined the SIR for lymphoma to be 1.4 for patients on thiopurine alone vs 4.4 for patients on thiopurine plus anti-TNF therapy, respectively. 11, 12 The increased risk of lymphoma with AZA/6-MP and anti-TNF therapy is a recognised safety risk in IBD, athough the relative contribution of AZA/6-MP may be more important than anti-TNF. This is as reported in the ECCO consensus on malignancies in IBD stating that in IBD patients treated with thiopurines, there is an excess risk of lymphoma [evidence level 1], which can be reversed by drug withdrawal [evidence level 3]. There is no evidence of an overall excess risk of lymphoma in IBD patients treated with anti-TNF agents alone. 9 Our data on lymphoproliferative disorder/ malignancy in CD further confirm recent findings reported on the total Danish IBD population in which Poisson regression, analysis adjusted for age in 10-year intervals, showed no increased overall cancer risk associated with anti-TNF therapy. Interestingly, this large Danish population-based study also showed that most site-specific cancers numerically declined after adjusting for AZA use, 11,12 a finding we noted in ENCORE as well. The results of ENCORE also confirm earlier findings from an Italian multicentre study where the incidence of neoplasia was comparable in both infliximab patients and matched controls. 14 Our finding that infliximab [Remicade ® ] exposure was associated with a decreased mortality rate is an interesting result. A similar observation was reported in CD patients treated with adalimumab. 15 Older age was a predictor of mortality in ENCORE, and it was the only predictor of mortality in the Leuven cohort. 7 The ENCORE registry has several weaknesses that are mostly intrinsic weaknesses of observational registry studies. First, a high number of patients did not stay on their initiated infliximab [Remicade ® ] treatment and many patients changed therapy during the long follow-up period, partly due to the typical progression of CD, where treatment step-up is often required. This issue was addressed because patients who switched to infliximab were included as a separate group in our analyses and exposure-adjusted analyses were performed. Second, no effectiveness data were collected in this safety registry and causal relationships between treatments and AEs could not be assessed. Still, ENCORE reflects the real-world routine clinical practice of CD in Europe during the study period.
Conclusions
In summary, infliximab [Remicade ® ] exposure vs non-exposure in ENCORE increased the risk of serious infections and haematological conditions, whereas no increased risk of lymphoproliferative disorders or malignancy was observed. Longer disease duration was associated with increases in both serious infection and lymphoproliferative disorder/malignancy rates. This large data set confirms the risk profile of infliximab in CD and justifies all efforts to closely monitor patient safety.
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